Bernard Adam (Bram) Slütter, Ph.D.

Postdoctoral research fellow
bernard-slutter@uiowa.edu 

Lab: 319-335-9919
Fax: 319-335-9006

Training and Awards

2006 M.S. (Pharmaceutical Sciences) Leiden University, The Netherlands
2007 Visiting scientist at the lab of Prof Veronique Préat at Université Catholique de Louvain (Brussels) , subsidised by Top Institute Pharma project number D5-106
2007 Co-organizer of the biannual meeting of the Global Pharmaceutical Educational Network (GPEN) in Leuven, Belgium
2011 Ph.D. Leiden University, The Netherlands. Supervisor: Prof Dr. Wim Jiskoot
2011-2013 Rubicon Fellowship, Netherlands Organization for Scientific Research (NWO)  

Research

Dissecting memory CD8 T-cell responses against influenza A.
Development of novel vaccine formulations that enhance memory CD8 T-cells formation.

Publications Pubmed

1. Bal SM*, Slütter B*, Verheul R, Bouwstra JA, Jiskoot W Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-dependent immunogenicity in mice. Eur J Pharm Sci. 2011 (in press)
2. Verheul RJ, Slütter B, Bal SM, Bouwstra JA, Jiskoot W, Hennink WE. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination. J Control Release. 2011 156(1):46-52
3. Bal SM, Slutter B, Jiskoot W, Bouwstra JA. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunization. Vaccine 2011 29(23): 4025-32
4. Slütter B*, Bal SM*, Zhi D, Jiskoot W, Bouwstra JA Adjuvant effect of cationic liposomes and CpG depends on administration route. Journal Controlled Release. 2011 154(2):123-30
5. Slütter B, Bal S, Que I, Kaijzel E, Löwik C, Bouwstra J, Jiskoot W. Antigen-adjuvant conjugates for nasal vaccination, an improvement over the use of nanoparticles? Mol Pharm 2010 7(6):2207-15
6. Slütter B, Keijzer C, Bal S, Que I, Kaijzel E, Löwik, Mallants R, Augustijns P, Broere F, van Eden W, Jiskoot W. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine, 2010 28(38):6282-91
7. Slütter B and Jiskoot W. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethly chitosan (TMC) nanoparticles for nasal vaccination. Journal Controlled Release 2010 148(1):117-21
8. Slütter B, Soema PC, Ding Z, Verheul R, Hennink W, Jiskoot W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. Journal Controlled Release. 2010 143(2):207-14.
9. Bal SM, Slütter B, van Riet E, Kruithof AC, Ding Z, Kersten GF, Jiskoot W, Bouwstra JA. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. Journal Controlled Release. 2010 142(3):374-83.
10. Slütter B*, Plapied L*, Fievez V, des Rieux A, Schneider Y, van Riet E, Jiskoot W, Préat V. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. Journal Controlled Release. 2009 138(2):113-21. 
11. Slütter B*, Hagenaars N*, Jiskoot W. Rational design of nasal vaccines. J Drug Target. 2008 16(1):1-17.
    
    * = both authors contributed equally to this study